Tag: biotech
ALS Drug Trial Fails to Slow Disease Progression
Denali Therapeutics halted the SAR443820 trial after a phase 2 study failed to slow functional...
Oveporexton Shows Symptom Improvement in Narcolepsy Type 1%
Oveporexton shows symptom improvement in narcolepsy type 1, improving wakefulness and quality of life.
Eight New Muscular Dystrophy Therapies Show Promise
Eight new muscular dystrophy therapies show promise in targeting disease mechanisms, moving beyond traditional care...
FDA fast-tracks first drug for MOGAD
The FDA fast-tracks satralizumab for MOGAD, a rare autoimmune disease. This decision could make it...
Private hospitals see revenue rise under new reform proposals
New health reform proposals may boost private hospital revenue and push up insurance premiums. See...
Firm seeks partner for AI and cloud growth
Healthcare leaders accelerate AI and cloud adoption to cut costs, but IT teams need partners...
NinjaOne streamlines healthcare IT management
NinjaOne streamlines healthcare IT management by reducing manual workloads and improving visibility across distributed environments....
Healthcare embraces innovation after pandemic shift
Healthcare innovation accelerates after pandemic shifts, replacing reactive models with predictive care for lasting transformation.
CMS Launches GLP-1 Bridge Program for $50/Month
CMS introduces GLP-1 Bridge Program for $50/month, expanding access to weight-loss meds. Learn how this...
Australia backs biotech with tax incentives
Australia backs biotech with tax incentives, offering strong research infrastructure and streamlined trials.